Oxford BioMedica

thinkerdoer has played an important role in the key message identification and articulation for Oxford BioMedica's annual reports over many years.

This FTSE main market listed business has developed over time as they continue delivery against their strategy; moving from a drug discovery business focused on finding new treatments for unmet needs, to a world leader at the centre of the gene and cell therapy industry. They are 'ideally placed' to take advantage of the fast evolving market as it grows into a multi-billion dollar industry.

As a series of annual reports dating back to the first one thinkerdoer and OxfordBioMedica produced together in 2010, they remain consistently among the very best in sector.